Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment;Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento

Actas Dermo-Sifiliograficas

Volumn 104, Issue 8, 2013, Pages 694-709

  Puig, L ^a   Carrascosa, J M ^b   Carretero, G ^c   De La Cueva, P ^d   Lafuente Urrez, R F ^e   Belinchon I ^f   Sanchez Regana M ^g   Garcia Bustinduy M ^h   Ribera, M ⁱ   Alsina, M ^j   Ferrandiz C ^b   Fonseca, E ^k   Garcia Patos V ^l   Herrera, E ^m   Estebaranz, J L López ⁿ   Marron S E ^o   Moreno, J C ^p   Notario, J ^q   Rivera, R ^r   Rodriguez Cerdeira, C ^s   Romero, A ^t   Ruiz Villaverde, R ^u   Taberner, R ^v   Vidal, D ^w   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^e Anatomía Patológica del Hospital Reina Sofía de Tudela   (Bulgaria)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^h HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

ⁱ Servicio de Cirugía General Y Aparato Digestivo   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL JUAN CANALEJO   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^o INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^p HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^q HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^r HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^s UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^t HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^u Servicio Andaluz de Salud   (Spain)

^v HOSPITAL SON LLÀTZER   (Spain)

^w Hospital de Sant Joan Despí Moisès Broggi   (Spain)

more..

Author keywords

Adalimumab; Biologic agents; Biologic therapy; Clinical practice guidelines; Etanercept; Infliximab; Psoriasis; Treatment; Ustekinumab

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; PRACTICE GUIDELINE; PSORIASIS;

ADALIMUMAB; BIOLOGIC AGENTS; BIOLOGIC THERAPY; BIOLÓGICOS; CLINICAL PRACTICE GUIDELINES; ETANERCEPT; GUÍA; INFLIXIMAB; PSORIASIS; TERAPIA BIOLÓGICA; TRATAMIENTO; TREATMENT; USTEKINUMAB;

ACITRETIN; ADULT; AGE FACTORS; ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DRUG SUBSTITUTION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; PHOTOCHEMOTHERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; PSORIASIS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPAIN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85047698707     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2013.04.013     Document Type: Short Survey

References (126)

1. C. Ferrandiz, X. Bordas, V. Garcia-Patos, S. Puig, R. Pujol, and A. Smandia Prevalence of psoriasis in Spain (Epiderma Project: phase i) J Eur Acad Dermatol Venereol 15 2001 20 23
2. L. Puig-Sanz La psoriasis, ¿una enfermedad sistémica? Actas Dermosifiliogr 98 2007 396 402
3. S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer Jr., and D.M. Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 3 Pt 1 1999 401 407
4. S. Prey, C. Paul, V. Bronsard, E. Puzenat, P.A. Gourraud, and S. Aractingi Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: A systematic review of the literature J Eur Acad Dermatol Venereol 24 Suppl 2 2010 31-55
5. A. García-Diez, C. Ferrándiz, F. Vanaclocha, L. Lizán, X. Badia, and G. Sellers What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian Region Dermatology 216 2008 137 151
6. J. Schmitt, and G. Wozel The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis Dermatology 210 2005 194 199
7. D.M. Pariser, J. Bagel, J.M. Gelfand, N.J. Korman, C.T. Ritchlin, and B.E. Strober National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity Arch Dermatol 143 2007 239 242
8. A. Robinson, M. Kardos, and A.B. Kimball Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis J Am Acad Dermatol 66 2012 369 375
9. V. Bronsard, C. Paul, S. Prey, E. Puzenat, P.A. Gourraud, and S. Aractingi What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature J Eur Acad Dermatol Venereol 24 Suppl 2 2010 17 22
10. L. Puig, X. Bordas, J.M. Carrascosa, E. Daudén, C. Ferrándiz, and J.M. Hernanz Documento de consenso sobre evaluación y tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología Actas Dermosifiliogr 100 2009 277 286
11. A. Menter, A. Gottlieb, S.R. Feldman, A.S. van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850
12. L. Puig, J.M. Carrascosa, E. Daudén, J.L. Sánchez-Carazo, C. Ferrándiz, and M. Sánchez-Regaña Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada/grave con agentes biológicos Actas Dermosifiliogr 100 2009 374 401
13. C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, and D. Chandler British Association of Dermatologists. British Association of Dermatologists' guidelines for use of biological interventions in psoriasis 2009 Br J Dermatol 161 2009 987 1019
14. D. Pathirana, A.D. Ormerod, P. Saiag, C. Smith, P.I. Spuls, and A. Nast European S3-guidelines on the systemic treatment of psoriasis vulgaris J European Acad Dermatol 23 Suppl 2 2009 5 70
15. K. Papp, W. Gulliver, C. Lynde, Y. Poulin, and J. Ashkenas Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: Overview J Cutan Med Surg 15 2011 210 219
16. S. Hsu, K.A. Papp, M.G. Lebwohl, J. Bagel, A. Blauvelt, and K.C. Duffin National Psoriasis Foundation Medical Board. Consensus guidelines for the management of plaque psoriasis Arch Dermatol 148 2012 95 102
17. A. Nast, W.H. Boehncke, U. Mrowietz, H.M. Ockenfels, S. Philipp, and K. Reich Deutsche Dermatologische Gesellschaft; Berufsverband Deutscher Dermatologen. German S3-guidelines on the treatment of psoriasis vulgaris (short version) Arch Dermatol Res 304 2012 87 113
18. L. Puig, E. Daudén, and J.M. Carrascosa Comentarios a las directrices europeas y británicas sobre el tratamiento de la psoriasis Actas Dermosifiliogr 101 2010 285 290
19. National Institute for Health and Clinical Excellence CG153 Psoriasis: full guideline [consultado 2 Jan 2013]. Disponible en: http://guidance.nice.org. uk/CG153/Guidance/pdf/English
20. N. Woolacott, N. Hawkins, A. Mason, A. Kainth, Z. Khadjesari, and Y.B. Vergel Etanercept and efalizumab for the treatment of psoriasis: A systematic review Health Technol Assess 10 2006 1 233 i-iv
21. E. Loveman, D. Turner, D. Hartwell, K. Cooper, and A. Clegg Infliximab for the treatment of adults with psoriasis Health Technol Assess 13 Suppl 1 2009 55 60
22. D. Turner, J. Picot, K. Cooper, and E. Loveman Adalimumab for the treatment of psoriasis Health Technol Assess 13 Suppl 2 2009 49 54
23. E. Gospodarevskaya, J. Picot, K. Cooper, E. Loveman, and A. Takeda Ustekinumab for the treatment of moderate to severe psoriasis Health Technol Assess 13 Suppl 3 2009 61 66
24. K. Reich, R. Sinclair, G. Roberts, C.E. Griffiths, M. Tabberer, and J. Barker Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis Curr Med Res Opin 24 2008 1237 1254
25. A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, and A. Menter Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials Br J Dermatol 159 2008 274 285
26. J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, and W. Kirch Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials Br J Dermatol 159 2008 513 526
27. N. Bansback, S. Sizto, H. Sun, S. Feldman, M.K. Willian, and A. Anis Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis Dermatology 219 2009 209 218
28. J.Y. Tan, S. Li, K. Yang, B. Ma, W. Chen, and C. Zha Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: A meta-analysis J Dermatolog Treat 22 2011 323 336
29. K. Reich, A.D. Burden, J.N. Eaton, and N.S. Hawkins Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials Br J Dermatol 166 2012 179 188
30. V.W. Lin, S. Ringold, and E.B. Devine Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A bayesian network meta-analysis Arch Dermatol 148 2012 1403 1410
31. T.C. Lucka, D. Pathirana, A. Sammain, F. Bachmann, S. Rosumeck, and R. Erdmann Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment J Eur Acad Dermatol Venereol 26 2012 1331 1344
32. S. Sizto, N. Bansback, S.R. Feldman, M.K. Willian, and A.H. Anis Economic evaluation of systemic therapies for moderate to severe psoriasis Br J Dermatol 160 2009 1264 1272
33. Y. Poulin, R. Langley, H.D. Teixeira, M.J. Martel, and S. Cheung Biologics in the treatment of psoriasis: Clinical and economic overview J Cutan Med Surg 13 Suppl 2 2009 S49 S57
34. S. De Portu, M. del Giglio, G. Altomare, F. Arcangeli, E. Berardesca, and P. Calzavara Pinton Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system Dermatol Ther 23 Suppl 1 2010 S7 S13
35. A.J. Blasco, P. Lázaro, C. Ferrándiz, A. García-Díez, and J. Liso Eficiencias de los agentes biológicos en el tratamiento de la psoriasis moderada-grave Actas Dermosifiliogr 100 2009 792 803
36. C. Ferrándiz, A. García, A.J. Blasco, and P. Lázaro Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis J Eur Acad Dermatol Venereol 26 2012 768 777
37. Enbrel [consultado 2 Jan 2013]. Disponible en: http://www.ema.europa.eu/ docs/es-ES/document-library/EPAR-Product-Information/human/000262/WC500027361. pdf
38. Humira [consultado 2 Jan 2013]. Disponible en: http://www.ema.europa.eu/ docs/es-ES/document-library/EPAR-Product-Information/human/000481/WC500050870. pdf
39. Remicade [consultado 2 Jan 2013]. Disponible en: http://www.ema.europa. eu/docs/es-ES/document-library/EPAR-Product-Information/human/000240/ WC500050888.pdf
40. Stelara [consultado 2 Jan 2013]. Disponible en: http://www.ema.europa.eu/ docs/es-ES/document-library/EPAR-Product-Information/human/000958/WC500058513. pdf
41. U. Mrowietz, K. Kragballe, K. Reich, P. Spuls, C.E. Griffiths, and A. Nast Definition of treatment goals for moderate to severe psoriasis: a European consensus Arch Dermatol Res 303 2011 1 10
42. L. Puig Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis J Eur Acad Dermatol Venereol 27 2013 e257 e260
43. K. Reich, and U. Mrowietz Treatment goals in psoriasis J Dtsch Dermatol Ges 5 2007 566 574
44. E.A. Brezinski, and A.W. Armstrong Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy PLoS One 7 2012 e33486
45. R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096
46. C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, and P.M. Mulani Efficacy, safety, and medication cost implications of adalimumab 40 mg weekly dosing in psoriasis patients with sub-optimal response to 40 mg every other week dosing: Results from an open-label study Br J Dermatol 167 2012 658 667
47. J. Van den Reek, P.P. van Lümig, W. Kievit, J. Zweegers, P.C. van de Kerkhof, and M. Seyger Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice J Dermatolog Treat 2013
48. R. Langley, M. Lebwohl, G. Krueger, P. Szapary, D. Chan, and M. Hsu Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: Results from the PHOENIX 2 long-term extension. Prague 21st European Association of Dermatology & Venereology (EADV) congress 27-30 September 2012 Poster 976
49. K. Reich, C. Griffiths, J. Barker, S. Chimenti, E. Daudén, and A. Giannetti Recommendations for the long-term treatment of psoriasis with infliximab: A dermatology expert group consensus Dermatology 217 2008 268 275
50. C. Leonardi, B. Strober, A.B. Gottlieb, B.E. Elewski, J.P. Ortonne, and P. van de Kerkhof Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study J Drugs Dermatol 9 2010 928 937
51. L. Puig Dose escalation may be effective in psoriasis patients with treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios Br J Dermatol 168 2013 674 676
52. B.E. Strober, Y. Poulin, F.A. Kerdel, R.G. Langley, Y. Gu, and S.R. Gupta Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study J Am Acad Dermatol 64 2011 671 681
53. A.B. Gottlieb, R.E. Kalb, A. Blauvelt, M.P. Heffernan, H.L. Sofen, and L.K. Ferris The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study J Am Acad Dermatol 67 2012 642 650
54. C.E. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, N. Yeilding ACCEPT Study Group Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
55. G. Pitarch, J.L. Sánchez-Carazo, L. Mahiques, and V. Oliver Efficacy of etanercept in psoriatic patients previously treated with infliximab Dermatology 216 2008 312 316
56. A. Down Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor a biologics and switched to ustekinumab Br J Dermatol 163 2010 424 437
57. R. Fernández Torres, S. Paradela, and E. Fonseca Long-term response to etanercept monotherapy in moderate to severe psoriasis. Assessment in daily practice by the maintenance of low values of PASI and BSA J Dermatolog Treat 23 2012 278 283
58. E.L. Baker, C.I. Coleman, K.M. Reinhart, O.J. Phung, L. Kugelman, and W. Chen Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic Review and Meta-Analyses Dermatol Ther (Heidelb) 2 2012 9
59. H. Torii, N. Sato, T. Yoshinari, and H. Nakagawa Japanese Infliximab Study Investigators. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab J Dermatol 39 2012 253 259
60. D.A. Revicki, M.K. Willian, A. Menter, J.H. Saurat, N. Harnam, and M. Kaul Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis Dermatology 216 2008 260 270
61. I. Garcia-Doval, G. Carretero, F. Vanaclocha, C. Ferrandiz, E. Daudén, and J.L. Sánchez-Carazo Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials Arch Dermatol 148 2012 463 470
62. A. Gottlieb, R. Matheson, N. Lowe, G. Krueger, S. Kang, and B. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
63. K. Reich, F. Nestle, K. Papp, J. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase iii, multicentre, double-blind trial Lancet 366 2005 1367 1374
64. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
65. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E.M. Griffiths, and A.M. Nakanishi A global phase iii randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
66. S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, and A. Wang Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase iii trial Lancet 36 2006 29 35
67. P.C. van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, and A. Kaszuba Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension Br J Dermatol 159 2008 1177 1185
68. B.E. Strober, J.J. Crowley, P.S. Yamauchi, M. Olds, and D.A. Williams Efficacy and safety results from a phase iii, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis Br J Dermatol 165 2011 661 668
69. A.B. Gottlieb, C. Leonardi, F. Kerdel, S. Mehlis, M. Olds, and D.A. Williams Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis Br J Dermatol 165 2011 652 660
70. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial Lancet 357 2001 1842 1847
71. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
72. A. Menter, S. Feldman, G. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to- severe plaque psoriasis J Am Acad Dermatol 56 2007 e1 e15
73. K. Gordon, R. Langley, C. Leonardi, D. Toth, M. Menter, and S. Kang Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open- label extension study J Am Acad Dermatol 55 2006 598 606
74. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortonne Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
75. A. Menter, S. Tyring, K. Gordon, A. Kimball, C. Leonardi, and R. Langley Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase iii trial J Am Acad Dermatol 58 2008 106 115
76. C. Leonardi, A. Kimball, K. Papp, N. Yeilding, C. Guzzo, and Y. Wang Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial PHOENIX 1 Lancet 371 2008 1665 1674
77. K. Papp, R. Langley, M. Lebwohl, G. Krueger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial PHOENIX 2 Lancet 371 2008 1675 1684
78. W. Sterry, J.P. Ortonne, B. Kirkham, D. Robertson, R. Pedersen, and J. Estojak Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial BMJ 340 2010 c147
79. R. Strohal, L. Puig, E. Chouela, T.F. Tsai, J. Melin, and B. Freundlich The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial) J Dermatolog Treat 24 2013 169 178
80. J. Barker, M. Hoffmann, G. Wozel, J.P. Ortonne, H. Zheng, and V. Hoogstraten Efficacy and safety of infliximab vs. methotrexate in patients with moderate to severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE 1) Br J Dermatol 165 2011 1109 1117
81. D. Thaci, P. Ortonne, S. Chimenti, D. Ghislain, P. Arenberge, and K. Kragballe A phase iiib, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study Br J Dermatol 163 2010 402 411
82. A. Kuhn, and T.A. Luger Psoriasis: Is ustekinumab superior to etanercept for psoriasis? Nat Rev Rheumatol 6 2010 500 501
83. V. Connor Anti-TNF therapies: A comprehensive analysis of adverse effects associated with immunosuppression Rheumatol Int 31 2011 327 337
84. D. Salmon-Ceron, F. Tubach, O. Lortholary, O. Chosidow, S. Bretagne, N. Nicolas RATIO group Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry Ann Rheum Dis 70 2011 616 623
85. G. Girolomoni, G. Altomare, F. Ayala, E. Berardesca, P. Calzavara-Pinton, and S. Chimenti Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis Immunopharmacol Immunotoxicol 34 2012 548 560
86. R. Navarro, E. Vilarrasa, P. Herranz, L. Puig, X. Bordas, and J.M. Carrascosa Safety and effectiveness of ustekinumab and anti-tumor necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C. A retrospective, multicentre study in a clinical setting Br J Dermatol 168 2013 609 616
87. D. Barco, L. Puig, and A. Alomar Treatment of moderate-severe psoriasis with etanercept in patients with chronic human immunodeficiency virus infection Actas Dermosifiliogr 101 Suppl 1 2010 77 81
88. L. Puig Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment J Eur Acad Dermatol Venereol 25 2011 1007 1011
89. A. Gottlieb, A. Menter, A. Mendelsohn, Y.K. Shen, S. Li, and C. Guzzo Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo controlled, crossover trial Lancet 373 2009 633 640
90. Z. Ash, C. Gaujoux-Viala, L. Gossec, E.M. Hensor, O. Fitzgerald, and K. Winthrop A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis Ann Rheum Dis 71 2012 319 326
91. P. Gisondi, G. Malara, and M. Ardigò The psoriatic patient profile for infliximab Eur Rev Med Pharmacol Sci 15 2011 1445 1451
92. W. Sterry, and P. van de Kerkhof Is «class effect» relevant when assessing the benefit/risk profile of a biologic agent? J Eur Acad Dermatol Venereol 26 Suppl 5 2012 9 16
93. K. Gordon, K. Papp, Y. Poulin, Y. Gu, S. Rozzo, and E.H. Sasso Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL J Am Acad Dermatol 66 2012 241 251
94. A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen on behalf of the PHOENIX 1 investigators Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study J Eur Acad Dermatol Venereol 2012 10.1111/jdv.12046
95. K.A. Papp, Y. Poulin, R. Bissonnette, M. Bourcier, D. Toth, and L. Rosoph Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population J Am Acad Dermatol 66 2012 e33 e45
96. A. Clemmensen, M. Spon, L. Skov, C. Zachariae, and R. Gniadecki Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris J Eur Acad Dermatol Venereol 25 2011 1037 1040
97. K. Papp, A. Menter, Y. Poulin, Y. Gu, and E.H. Sasso Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study J Eur Acad Dermatol Venereol 27 2013 634 642
98. J.P. Ortonne, C.E.M. Griffiths, M. Dauden, R. Strohal, D. Robertson, and R. Pedersen The efficacy and safety of continuous versus interrupted etanercept treatment in patients with moderate to severe psoriasis over 54 weeks: The CRYSTEL study Expert Rev Dermatol 3 2008 657 665
99. J.P. Ortonne, A. Taïeb, A.D. Ormerod, D. Robertson, J. Foehl, and R. Pedersen Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept Br J Dermatol 161 2009 1190 1195
100. Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L. Efficacy and Safety of Infliximab as Continuous or Intermittent Therapy in Patients With Moderate-to-Severe Plaque Psoriasis: Results of a Randomised, Long-Term Extension Trial (RESTORE2). Br J Dermatol. 2013. http://dx.doi.org/10.1111/bjd. 12404.
101. L.L. Lecluse, R.J. Driessen, P.I. Spuls, E.M. de Jong, S.O. Stapel, and M.B. van Doorn Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis Arch Dermatol 146 2010 127 132
102. S. Garcês, J. Demengeot, and E. Benito-Garcia The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis Ann Rheum Dis 2012
103. E. Martin-Mola, C. Plasencia, and A. Balsa Cambio a un segundo anti-TNF cuando ha fracasado el primero (switching) en la artritis reumatoide. ¿Qé nos aportan los nuevos datos sobre inmunogenicidad? Reumatol Clin Supl 6 2011 23 28
104. P.A. Foley, C. Quirk, J.R. Sullivan, C. Dolianitis, S.P. Hack, and K. Thirunavukkarasu Combining etanercept with traditional agents in the treatment of psoriasis: A review of the clinical evidence J Eur Acad Dermatol Venereol 24 2010 1135 1143
105. I. Belinchón, and I. Ballester Combined therapy with etanercept and systemic drugs or phototherapy Actas Dermosifiliogr 101 Suppl 1 2010 40 44
106. L. Kircik, J. Bagel, N. Korman, A. Menter, C.A. Elmets, J. Koo Unite Study Group Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): Efficacy, safety, and patient-reported outcomes J Drugs Dermatol 7 2008 245 253
107. C. De Simone, M. D'Agostino, R. Capizzi, A. Capponi, A. Venier, and G. Caldarola Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis Eur J Dermatol 21 2011 568 572
108. T. Gambichler, C. Tigges, N. Scola, J. Weber, M. Skrygan, and F.G. Bechara Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks Br J Dermatol 164 2011 1383 1386
109. C.W. Lynde, A.K. Gupta, L. Guenther, Y. Poulin, A. Levesque, and R. Bissonnette A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept J Dermatolog Treat 23 2012 261 267
110. K.K. Park, J.J. Wu, and J. Koo A randomized, «head-to-head» pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients J Eur Acad Dermatol Venereol 2012 10.1111/j.1468-3083.2012.04611.x
111. C. Zachariae, N.J. Mørk, T. Reunala, H. Lorentzen, E. Falk, and S.L. Karvonen The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy Acta Derm Venereol 88 2008 495 501
112. R.J. Driessen, P.C. van de Kerkhof, and E.M. de Jong Etanercept combined with methotrexate for high-need psoriasis Br J Dermatol 159 2008 460 463
113. A.B. Gottlieb, R.G. Langley, B.E. Strober, K.A. Papp, P. Klekotka, and K. Creamer A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis Br J Dermatol 167 2012 649 657
114. E.J. Lee, M.K. Shin, and N.I. Kim A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis Ann Dermatol 22 2010 138 142
115. P. Gisondi, M. del Giglio, C. Cotena, and G. Girolomoni Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial Br J Dermatol 158 2008 1345 1349
116. J. Bagel Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis J Drugs Dermatol 10 2011 366 371
117. S. Philipp, D. Wilsmann-Theis, A. Weyergraf, S. Rotterdam, Y. Frambach, and S. Gerdes Combination of adalimumab with traditional systemic antipsoriatic drugs-a report of 39 cases J Dtsch Dermatol Ges 10 2012 821 837
118. M. Dalaker, and J.H. Bonesrønning Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort J Eur Acad Dermatol Venereol 23 2009 277 282
119. R.B. Warren, B.C. Brown, A.J. Carmichael, and C.E. Griffiths Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate Clin Exp Dermatol 34 2009 415 416
120. Q.U. Kamili, A. Miner, A. Hapa, and A. Menter Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: A review J Drugs Dermatol 10 2011 539 544
121. C.R. Mehren, and R. Gniadecki Dose-creep of Infliximab during psoriasis treatment: An observational study Acta Derm Venereol 92 2012 355 357
122. P. Wolf, W. Weger, F.J. Legat, T. Posch-Fabian, A. Gruber-Wackernagel, and M. Inzinger Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: A randomized intraindividual trial Br J Dermatol 166 2012 147 153
123. C. Ferrándiz, and J.M. Carrascosa Transition of classical systemic treatments to etanercept Actas Dermosifiliogr 101 Suppl 1 2010 45 49
124. J.M. Carrascosa, J.L. López-Estebaranz, G. Carretero, E. Daudén, C. Ferrándiz, D. Vidal Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología Narrowband UV-B, monochromatic excimer laser, and photodynamic therapy in psoriasis: A consensus statement of the Spanish Psoriasis Group Actas Dermosifiliogr 102 2011 175 186
125. G. Carretero, L. Puig, L. Dehesa, J.M. Carrascosa, M. Ribera, M. Sánchez-Regaña Grupo de Psoriasis de la AEDV Guidelines on the use of methotrexate in psoriasis Actas Dermosifiliogr 101 2010 600 613
126. Carretero G, Ribera M, Belinchón I, Carrascosa JM, Puig L, Ferrandiz C, et al. Guidelines for the Use of Acitretin in Psoriasis. Actas Dermosifiliogr. 2013.